MARKET WIREYahoo! Finance Canada • 1d ago
Absci Corporation (ABSI) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
Why ABSI Stock dropped -12.94% Today — RQD Quant Desk Flash
$9.69 -12.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $9.45
Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.91B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ABSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $9.69 (-12.94% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABSI ranks #382 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ABSI compare to OABI and NRC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ABSI?
▼
Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $336.9M in revenue (+7330.3% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $9.45 (-2.52%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY ABSI SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (39% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$9.10-0.3% Next Q
36
Q2 (-2Q)Grade E$9.07+16.5% Next Q
39
Q3 (-1Q)Grade D$10.57-8.3% Next Q
41
CurrentGrade D$9.69-6.5% Hist 90D α
44
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABSI Turnaround Squeeze
While ABSI currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.60) and Max Pain ($10.17) forces dealer call-delta covering toward $13.18.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABSI Stock dropped -12.94% Today — RQD Quant Desk Flash
Absci Corporation (ABSI) dropped -12.94% to $9.69, trading at 72% of its 52-week range ($2.24 – $12.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 72% of its 52-week range ($2.24 – $12.55) with RSI-14 at 55.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $9.69 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ABSI Headlines & Catalysts
CATALYSTYahoo Finance • 1d ago
Absci (ABSI) Stock Seems Rich Against Its Book Value BackdropYahoo Finance report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Absci Corporation Estimates – NASDAQ:ABSITradingView report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Absci (NASDAQ:ABSI) Stock Jumps 13.2% - Still a Buy?MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's WhyMarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Absci Corporation (ABSI) Slides 13.47% to $10.47 as Shares Retreat Toward Key Support - Call Resistancehttps://www.siam.in/ report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Absci Corporation (NASDAQ:ABSI) Stock Rated "Moderate Buy" by Sell-Side AnalystsMarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back RallyKey TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s business.
RISK WATCHYahoo • 4d ago
Does Positive Hair Loss Trial Data Change The Bull Case For Absci Stock?Absci reported positive interim Phase 1 data for ABS-201 in pattern hair loss, including an estimated half-life of at least 65 days and timelines for proof-of-concept data in the second half of 2026 and full data in earl
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABSI)
- ✓Walkthrough of ABSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +72.42%▲ ASCENDING CHANNEL
2026-11-03O $12.10H $12.10L $9.69C $9.69VOL 4.57M
RES: $13.05SUP: $8.43SMA50: $9.60SMA200: $6.58
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +7330.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABSI)
Health Care Rank #382 of 1015
⚔️ OABI vs ABSI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABSI vs. OABI, NRC, ICLR, CRL)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #382 by composite RQD confidence (44/100, grade D) and #264 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with ABSI at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABSI
ACTIVE
Absci Corporation | D | 44/100 | — | — | -35.0% | -12.94% | $1.91B | Benchmark Subject |
| OABI OmniAb Inc. | D | 44/100 | — | — | -22.6% | -0.39% | $742.9M | /oabi-vs-absi → |
| NRC NRC Health | C+ | 67/100 | 44.8x | — | 21.0% | +1.80% | $527.1M | /nrc-vs-absi → |
| ICLR ICON plc | B | 72/100 | 71.9x | — | 3.1% | -2.94% | $16.18B | /iclr-vs-absi → |
| CRL Charles River Laboratories International Inc. | C | 64/100 | — | — | 0.4% | -5.81% | $17.16B | /crl-vs-absi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672688 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $336.9M (+7330.3% vs. FY2024 revenue of $4.5M , and +5791.7% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $336.9M | -$115.2M | -$92.9M | -$94.0M | $216.3M | — |
| FY2024 (FY) | 2024-12-31 | $4.5M | -$103.1M | -$72.4M | -$72.8M | $213.6M | — |
| FY2023 (FY) | 2023-12-31 | $5.7M | -$110.6M | -$64.6M | -$64.6M | — | — |
3. ABSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $9.69 (-12.94% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABSI ranks #382 in composite RQD confidence.
How does ABSI compare to OABI and NRC in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABSI?
Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $336.9M in revenue (+7330.3% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABSI trading relative to its 50-day, 200-day, and 52-week technical levels?
ABSI last traded at $9.69 (-12.94% on volume of 3,813,257 shares), positioning the stock +0.94% above its 50-day simple moving average ($9.60) and +47.26% above its 200-day simple moving average ($6.58). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 72.3% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.48 to $10.90).
ROARABLE RATING BRIEF • RQD 44/100 (D)
✓ SEC XBRL & RQD VERIFIED
ABSI — Absci Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Absci Corporation (ABSI) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.69 (-12.94% 1D, market capitalization $1.91B).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -4.53%.
- Whale 13F & Options Flow (17/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Absci Corporation (ABSI) is a NASDAQ-listed issuer..
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Absci Corporation (ABSI) reported $336.9M in annual revenue (up from $4.5M in FY2024, +7330.3% YoY) and -$115.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.7M revenue, -$110.6M net income) through FY2025, ABSI scaled operating cash flow to -$92.9M and free cash flow to -$94.0M, backed by $216.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 44/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -4.53% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $2.24 – $12.55 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Sector and industry classification are given in the profile only.
- Key Question #1: Can ABSI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $336.9M and free cash flow of -$94.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ABSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ABSI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Absci Corporation (ABSI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Absci Corporation (ABSI) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop Yahoo Finance report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Absci Corporation Estimates – NASDAQ:ABSI TradingView report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Absci (NASDAQ:ABSI) Stock Jumps 13.2% - Still a Buy? MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Absci Corporation (ABSI) Slides 13.47% to $10.47 as Shares Retreat Toward Key Support - Call Resistance https://www.siam.in/ report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71 MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Absci Corporation (NASDAQ:ABSI) Stock Rated "Moderate Buy" by Sell-Side Analysts MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ABSI Bull vs. Bear Conversation Board — What's Your Call at $9.69?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABSI 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $14.14 (+27.0%)
📌 Pinned Debate Institutional accumulation and options positioning (17 / 20 whale 13F pillar) is the rating's strongest signal.
Institutional accumulation and options positioning (17 / 20 whale 13F pillar) is the rating's strongest signal.. When you look under the hood at ABSI, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (17/20) has been quietly accumulating below $12.55. My 12M target is $14.14.
RetailWhale_TX 🐂 BULL
@ForensicBear Shorting a 17/20 institutional whale-flow stock at $11.13 is dangerous when funds are rotating into Health Care.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $9.24 (-17.0%)
Spot @ $11.13 Negative ROIC of -35% and revenue falling to $0.0M in FY 2025 leave the business without cash-generating support.
Careful chasing ABSI at $11.13. Negative ROIC of -35% and revenue falling to $0.0M in FY 2025 leave the business without cash-generating support.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.24 on multiple compression.